HUP0302723A2 - Piperidin- vagy piperazincsoporttal szubsztituált N-hidroxi-formamidinek mint metalloproteáz inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítményekre - Google Patents
Piperidin- vagy piperazincsoporttal szubsztituált N-hidroxi-formamidinek mint metalloproteáz inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítményekreInfo
- Publication number
- HUP0302723A2 HUP0302723A2 HU0302723A HUP0302723A HUP0302723A2 HU P0302723 A2 HUP0302723 A2 HU P0302723A2 HU 0302723 A HU0302723 A HU 0302723A HU P0302723 A HUP0302723 A HU P0302723A HU P0302723 A2 HUP0302723 A2 HU P0302723A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- alkyl
- atom
- halogen atom
- carbon
- Prior art date
Links
- 102000005741 Metalloproteases Human genes 0.000 title 1
- 108010006035 Metalloproteases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- LMRCKXYHPYNEJV-UHFFFAOYSA-N piperazine;piperidine Chemical group C1CCNCC1.C1CNCCN1 LMRCKXYHPYNEJV-UHFFFAOYSA-N 0.000 title 1
- 229910052799 carbon Inorganic materials 0.000 abstract 8
- 125000005843 halogen group Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 2
- 150000001721 carbon Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940091173 hydantoin Drugs 0.000 abstract 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 abstract 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- -1 2-pyridyloxy group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229910052757 nitrogen Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 abstract 1
- 125000004149 thio group Chemical group *S* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/16—Halogen atoms; Nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A találmány (I) általános képletű vegyületekre vonatkozik - aképletben B a 3-as vagy 4-es helyzetben halogénatommal vagy trifluor-metilcsoporttal monoszubsztituált vagy a 3,4-helyzetben azonos vagyeltérő halogénatomokkal diszubsztituált fenilcsoportot; a 4-es, 5-ösvagy 6-os helyzetben halogénatommal, trifluor-metil-csoporttal,cianocsoporttal vagy 1-4 szénatomos alkilcsoporttal monoszubsztituált2-piridil- vagy 2-piridil-oxi-csoportot; vagy a 6-os helyzetben adottesetben halogénatommal vagy 1-4 szénatomos alkilcsoporttalszubsztituált 4-pirimidinil-csoportot jelent; X szénatomot vagynitrogénatomot jelent; és R1 jelentése trimetil-1-hidantoin-(2-4szénatomos alkil)-csoport, trimetil-3-hidantoin-(2-4 szénatomosalkil)-csoport, a 3-as vagy 4-es helyzetben halogénatommal, trifluor-metil-csoporttal, tiocsoporttal, 1-3 szénatomos alkilcsoporttal vagy1-3 szénatomos alkoxicsoporttal monoszubsztituált fenil- vagy (2-4szénatomos alkil)-fenilcsoport, fenil-SO2NH-(2-4 szénatomos alkil)-csoport, 2-piridilcsoport, 2-piridil-(2-4 szénatomos alkil)-csoport,3-piridilcsoport, 3-piridil-(2-4 szénatomos alkil)-csoport, 2-pirimidin-SCH2CH2-csoport, adott esetben halogénatommal, trifluor-metilcsoporttal, 1-3 szénatomos alkilcsoporttal vagy 1-3 szénatomosalkoxicsoporttal monoszubsztituált 2- vagy 4-pirimidinil-(2-4szénatomos alkil)-csoport, adott esetben halogénatommal szubsztituált2-pirazinil-csoport, vagy adott esetben halogénatommal szubsztituált2-pirazinil-(2-4 szénatomos alkil)-csoport. A találmány kiterjed avegyületek előállítására, alkalmazására, és ezeket tartalmazógyógyszerkészítményekre. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00400467 | 2000-02-21 | ||
| PCT/GB2001/000624 WO2001062742A1 (en) | 2000-02-21 | 2001-02-15 | Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0302723A2 true HUP0302723A2 (hu) | 2003-11-28 |
| HUP0302723A3 HUP0302723A3 (en) | 2007-09-28 |
Family
ID=8173564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0302723A HUP0302723A3 (en) | 2000-02-21 | 2001-02-15 | Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases, process for their preparation and pharmaceutical compositions containing them |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US6734183B2 (hu) |
| EP (1) | EP1261590B1 (hu) |
| JP (1) | JP4256095B2 (hu) |
| KR (1) | KR20020073594A (hu) |
| CN (1) | CN1247547C (hu) |
| AR (1) | AR029657A1 (hu) |
| AT (1) | ATE553097T1 (hu) |
| AU (1) | AU783284B2 (hu) |
| BG (1) | BG65276B1 (hu) |
| BR (1) | BR0108501A (hu) |
| CA (1) | CA2396965C (hu) |
| CO (1) | CO5241356A1 (hu) |
| CZ (1) | CZ20022828A3 (hu) |
| EE (1) | EE200200462A (hu) |
| HU (1) | HUP0302723A3 (hu) |
| IL (1) | IL150806A0 (hu) |
| IS (1) | IS6507A (hu) |
| MX (1) | MXPA02008111A (hu) |
| MY (1) | MY128164A (hu) |
| NO (1) | NO323765B1 (hu) |
| NZ (1) | NZ520104A (hu) |
| PL (1) | PL365909A1 (hu) |
| RU (1) | RU2283306C2 (hu) |
| SA (1) | SA01220167B1 (hu) |
| SG (1) | SG127737A1 (hu) |
| SK (1) | SK287071B6 (hu) |
| TW (1) | TWI276632B (hu) |
| UA (1) | UA73155C2 (hu) |
| WO (1) | WO2001062742A1 (hu) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0119473D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca | Compounds |
| GB0119472D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
| GB0119474D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
| ES2319970T3 (es) | 2001-09-07 | 2009-05-18 | Kaken Pharmaceutical Co., Ltd. | Derivados de acido hidroxamico inverso. |
| SE0301922D0 (sv) | 2003-06-27 | 2003-06-27 | Astrazeneca Ab | Novel compounds |
| EP1657240A4 (en) | 2003-08-18 | 2009-04-08 | Fujifilm Finechemicals Co Ltd | PYRIDYLTETRAHYDROPYRIDINE, PYRIDYLPIPERIDINE AND METHOD FOR THE PRODUCTION THEREOF |
| GB0427403D0 (en) | 2004-12-15 | 2005-01-19 | Astrazeneca Ab | Novel compounds I |
| WO2007060132A1 (en) * | 2005-11-24 | 2007-05-31 | Laboratoires Serono S.A. | N-hydroxyamide derivatives and use thereof |
| GB0617367D0 (en) * | 2006-09-02 | 2006-10-11 | Astrazeneca Ab | Novel process |
| JP5539965B2 (ja) | 2008-04-28 | 2014-07-02 | レバレジオ コーポレイション | 多発性硬化症を治療するための組成物および方法 |
| US8765814B2 (en) * | 2010-07-08 | 2014-07-01 | Kaken Pharmaceutical Co., Ltd. | N-hydroxyformamide derivative and medicament containing same |
| PT3116859T (pt) | 2014-03-12 | 2018-11-15 | Chong Kun Dang Pharmaceutical Corp | Novos compostos como inibidores de histona-desacetilase 6 e composições farmacêuticas que os compreendem |
| BR112021006407A8 (pt) | 2018-10-04 | 2022-12-06 | Inst Nat Sante Rech Med | uso de inibidores do egfr para ceratodermas |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998016514A1 (en) | 1996-10-16 | 1998-04-23 | American Cyanamid Company | Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| US6376506B1 (en) | 1997-01-23 | 2002-04-23 | Syntex (U.S.A.) Llc | Sulfamide-metalloprotease inhibitors |
| ZA98376B (en) | 1997-01-23 | 1998-07-23 | Hoffmann La Roche | Sulfamide-metalloprotease inhibitors |
| DE69807845T2 (de) * | 1997-01-23 | 2003-06-05 | Hoffmann La Roche | Sulfamide-metalloprotease inhibitoren |
| US6482827B1 (en) | 1997-07-10 | 2002-11-19 | Pharmacia & Upjohn S.P.A. | Matrix metalloproteinase inhibitors |
| JP2001500533A (ja) * | 1997-07-10 | 2001-01-16 | フアルマシア・エ・アツプジヨン・エツセ・ピー・アー | マトリックスメタロプロテイナーゼ・インヒビター |
| US6235786B1 (en) | 1997-08-06 | 2001-05-22 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
| US6294573B1 (en) | 1997-08-06 | 2001-09-25 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
| US6130220A (en) | 1997-10-16 | 2000-10-10 | Syntex (Usa) Inc. | Sulfamide-metalloprotease inhibitors |
| CA2317455C (en) | 1998-01-30 | 2011-01-25 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives |
| JP2002523492A (ja) | 1998-08-29 | 2002-07-30 | ブリティッシュ バイオテック ファーマシューティカルズ リミテッド | タンパク質分解酵素阻害剤としてのヒドロキサム酸誘導体 |
| GB9919776D0 (en) * | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
-
2001
- 2001-02-15 JP JP2001562524A patent/JP4256095B2/ja not_active Expired - Fee Related
- 2001-02-15 CN CNB018053920A patent/CN1247547C/zh not_active Expired - Fee Related
- 2001-02-15 UA UA2002075698A patent/UA73155C2/uk unknown
- 2001-02-15 RU RU2002118301/04A patent/RU2283306C2/ru not_active IP Right Cessation
- 2001-02-15 NZ NZ520104A patent/NZ520104A/en unknown
- 2001-02-15 SK SK1197-2002A patent/SK287071B6/sk not_active IP Right Cessation
- 2001-02-15 EP EP01905885A patent/EP1261590B1/en not_active Expired - Lifetime
- 2001-02-15 AT AT01905885T patent/ATE553097T1/de active
- 2001-02-15 BR BR0108501-8A patent/BR0108501A/pt not_active Application Discontinuation
- 2001-02-15 AU AU33855/01A patent/AU783284B2/en not_active Ceased
- 2001-02-15 CZ CZ20022828A patent/CZ20022828A3/cs unknown
- 2001-02-15 EE EEP200200462A patent/EE200200462A/xx unknown
- 2001-02-15 IL IL15080601A patent/IL150806A0/xx not_active IP Right Cessation
- 2001-02-15 MX MXPA02008111A patent/MXPA02008111A/es active IP Right Grant
- 2001-02-15 HU HU0302723A patent/HUP0302723A3/hu unknown
- 2001-02-15 PL PL01365909A patent/PL365909A1/xx not_active Application Discontinuation
- 2001-02-15 WO PCT/GB2001/000624 patent/WO2001062742A1/en active IP Right Grant
- 2001-02-15 CA CA2396965A patent/CA2396965C/en not_active Expired - Fee Related
- 2001-02-15 SG SG200404773A patent/SG127737A1/en unknown
- 2001-02-15 KR KR1020027010762A patent/KR20020073594A/ko active Search and Examination
- 2001-02-19 MY MYPI20010723A patent/MY128164A/en unknown
- 2001-02-20 CO CO01013250A patent/CO5241356A1/es not_active Application Discontinuation
- 2001-02-21 US US09/788,687 patent/US6734183B2/en not_active Expired - Fee Related
- 2001-02-21 AR ARP010100790A patent/AR029657A1/es not_active Application Discontinuation
- 2001-02-27 TW TW090104516A patent/TWI276632B/zh not_active IP Right Cessation
- 2001-06-23 SA SA01220167A patent/SA01220167B1/ar unknown
-
2002
- 2002-08-14 BG BG107003A patent/BG65276B1/bg unknown
- 2002-08-16 IS IS6507A patent/IS6507A/is unknown
- 2002-08-20 NO NO20023956A patent/NO323765B1/no not_active IP Right Cessation
-
2004
- 2004-02-26 US US10/787,813 patent/US7122551B2/en not_active Expired - Fee Related
-
2006
- 2006-08-24 US US11/509,490 patent/US20060287338A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0302723A2 (hu) | Piperidin- vagy piperazincsoporttal szubsztituált N-hidroxi-formamidinek mint metalloproteáz inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítményekre | |
| HUP0400467A2 (hu) | 2-Iminopirrolidin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HRP20020712B1 (hr) | Farmaceutske strukture koje sadrže derivate azetidina, novi derivati azetidina i njihovo pripremanje | |
| HUP0302487A2 (hu) | Új mandulasavszármazékok és felhasználásuk trombin inhibitorokként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| NO20052755D0 (no) | Krystallmodifikasjon av et N-fenyl-2-pyrimidinaminderivat, fremgangsmate for dens fremstilling og dens anvendelse. | |
| KR870001196A (ko) | 피리딘 화합물과 그의 제법 및 그를 함유하는 약학조성물 | |
| HUP0101599A2 (hu) | Heterociklussal szubsztituált amidok, előállításuk és alkalmazásuk, valamint ezeket a vegyületeket tartalmazó gyógyszerkészítmények | |
| BG108038A (en) | Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes | |
| HUP0103987A2 (en) | Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates | |
| KR930005992A (ko) | 루코트리엔 생합성 억제제 | |
| HUP0301501A2 (hu) | Glükagon antaagonista/inverz agonista vegyületek, ezeket tartalmazó gyógyászati készítmények, valamint a vegyületek alkalmazása gyógyászati készítmények előállítására | |
| HUP0301167A2 (hu) | Neurológiai rendellenességek kezelésére felhasználható szulfonil-pirrolidin-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| AR056582A1 (es) | COMPUESTOS DE PIRAZOLIL UREA CON ACTIVIDAD INHIBITORIA DE CINASA P38 Y FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE | |
| DK0869947T3 (da) | Barbitursyrederivater, fremgangsmåder til fremstilling deraf og farmaceutiske midler, der indeholder disse forbindelser | |
| HUP0303034A2 (hu) | Új 7-azaindol-származékok, foszfodiészteráz-4 inhibitorjakénti alkalmazásuk és eljárás az előállításukra | |
| ME00428B (me) | 5-hlor0-3-(4-metansulfonilfenil)-6'-metil-(2,3')bipiridinil u čistom kristalnom obliku i postupak sinteza | |
| RU98117621A (ru) | Новые производные пиперазина и пиперидина, способ их получения, фармкомпозиция на их основе, способ лечения, промежуточный продукт | |
| PE20050329A1 (es) | Derivados de nicotinamida como inhibidores de fosfodiesterasa pde4 | |
| RU2002118301A (ru) | Пиперидин- и пиперазин-замещенные n-гидроксиформамиды в качестве ингибиторов металлопротеиназ | |
| HUP0500026A2 (hu) | N-heteroaril-nikotinamid-származékok | |
| TR200402720T4 (tr) | Metalloproteaz inhibitörleri olarak 2-(4-piridinil)-benzofüran'lar | |
| HUP0003155A2 (hu) | Eljárás COX-2 inhibitorként alkalmazható 2-aril-3-aril-5-halogénpiridin-származékok előállítására | |
| HUP0303045A2 (hu) | Pirimidinszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| MXPA02011352A (es) | Nuevos derivados de benzofurano. | |
| HUP0303185A2 (hu) | GlyT-1 inhibitorok, eljárás előállításukra, és eljárásban használt köztitermékek és a vegyületeket tartalmazó gyógyászati készítmények |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |